Which are the 10 biggest FTSE-listed healthcare stocks?

Summary

  • The pandemic has made people more aware of the importance of research and development in pharmaceuticals, making Healthcare stocks the flavour of the season.
  • AstraZeneca, Dechra Pharmaceuticals are some of the many healthcare stocks that are doing well.

Healthcare stocks are the flavour of the season. The pandemic has made people more aware of the importance of research and development in pharmaceuticals. This has also made investors more interested in healthcare stocks as a potential investment option.

                                  Copyright © 2021 Kalkine Media

Here are 10 FTSE listed healthcare stocks that have had a sound run in the market.

  1. AstraZeneca Plc (LON: AZN)

The share of the company has a year-to-date return of 17.39 per cent and a market capitalisation of £113,661.17 million. It has a dividend yield of 2.41 per cent.

For the first quarter, total revenue increased 15 per cent to $7,320 million from $6,354 million in the same period a year ago. Profit after tax increased to $1,562 million from $750 million. Operating profit was up 55 per cent to $1,895 million from $1,220 million.

For FY2021, the total revenue of the company is expected to be up modestly. Faster growth in core earnings per share (EPS) is expected to be between $4.75 to $5.00.

  1. Glaxosmithkline Plc (LON: GSK)

Glaxosmithkline shares have a year-to-date return of 5.74 per cent and a market capitalisation of £72,305.17 million. The shares have a dividend yield 5.63 per cent.

For the first quarter of 2021, the company’s sales dropped 22 per cent to £2,480 million from £3,199 million in the same period a year ago. Turnover fell 18 per cent to £7,418 million from £9,090 million a year ago. Profit after tax was down 25 per cent to £1,260 million from £1,679 million.

For the full year of 2021, the company expects adjusted EPS to fall in the range of a mid to high-single digit percentage.

  1. Hikma Pharmaceuticals (LON: HIK)

Hikma shares have a one-year return of 15.19 per cent and a market capitalisation of £5,967.37 million. Its shares have a dividend yield of 1.43 per cent.

For the full year of 2021, the company expects its core revenue from global Injectables sees a growth in the mid-single digits. Core operating margin is expected to be within 37 per cent to 38 per cent. In the generic segment, the company’s revenue is expected to be towards the top range of the guidance of $770 million to $810 million, while the core operating margin would be around 20 per cent.

  1. Dechra Pharmaceuticals (LON: DPH)

The share of this company has a market capitalisation of £4,938.95 million and a year-to-date return of 31.30 per cent. Its one-year return was 54.82 per cent.

In a trading update the company said that it continues to benefit from lower underlying selling, general and administration (SG&A) costs because of the pandemic, coupled with robust market fundamentals. Further easing of lockdown norms as well as the completion of the pre-Brexit inventory, makes the board confident that the strong performance would be maintained for the whole year.

  1. Genus Plc (LON: GNS)

Genus shares have a market capitalisation of £3,327.45 million, and a one-year return of 44.39 per cent. The year-to-date return of the stock stood at 21.54 per cent.

For the half year ended 31 December 2020, revenue grew 6 per cent to £285.7 million from £270.7 million in the same period a year ago. Profit before tax was up 32 per cent to £48.4 million from 36.6 million last year.

  1. Indivior Plc (LON: INDV)

Indivior shares have a year-to-date return of 46.69 per cent and a one-year return of 75.77 per cent. The stocks market capitalisation stands at £1,173.92 million.

The company raised its guidance for FY21 net revenue to be in the range of $705 million to $740 million from the previous guidance of $625 million, on the back of strong performance from Sublocade. Sublocade’s net revenue is expected to be in the range of $210 million to $230 million from the previously estimated $185 million to $210 million.

  1. Oxford Biomedical (LON: OXB)

Oxford Biomedical shares have a one-year return of 79.29 per cent and a year-to-date return of 33.86 per cent. The current market capitalisation of the stock stands at £1,131.51 million.

For the full year ended 31 December 2020, the company’s revenues were up 37 per cent to £87.7 million from £64.1 million a year ago. Revenues from bioprocessing and commercial development were up by 45 per cent to £68.5 million from £47.3 million a year ago. Its operating loss fell to £5.7 million from a loss of £14.5 million a year ago.

  1. Puretech Health (LON: PRTC)

Puretech shares have a one-year return of 26.32 per cent and a market capitalisation of £975.64 million.

The company’s cash and cash equivalents were at $443.4 million as of 31 March 2021, compared to $349.4 million on 31 December 2020. It received one FDA Clearance in marketing for the beginning of a phase 3 program and two European Marketing Authorizations. The company raised post period $247.8 million in 2020 and $473.2 million in 2021.

  1. Vectura Group (LON: VEC)

Vectura shares have a market capitalisation of £815.30 million and a one-year return of 12.94 per cent.

For the full year of 2020, the company’s revenue was up 6.9 per cent to £190.6 million from £178.3 million a year ago. The company’s adjusted EBITDA was up 41.7 per cent to £61.5 million from £43.4 million a year ago. Cash and cash equivalents were up 6.1 per cent to £78.6 million from £74.1 million.

  1. UDG Healthcare (LON: UDG)

The shares have a one-year return of 48.37 per cent and a year-to-date return of 37.44 per cent. The market capitalisation of the stock stands at £2,698.64 million.

For the first quarter up to 31 December 2020, the company’s financial year started on a good note and operating profit at constant currency for the quarter to 31 December 2020 is expected to be more than the same quarter last year. The company is acquiring PHMR Limited for about £32 million.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is not authorised or regulated by the Financial Conduct Authority to provide regulated advice. The purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. The Content is guidance about the different types of investments that are available and sets out general principles to continue before making investment decisions. Kalkine Media is neither authorised nor qualified to provide regulated investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from an appropriately authorised and/or qualified financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.